Response Genetics, Inc. (NASDAQ:RGDX)
CAPS Rating:
The Company is engaged in the research and development of its own pharmacogenomic cancer diagnostic tests based on its proprietary technologies.
The Company is engaged in the research and development of its own pharmacogenomic cancer diagnostic tests based on its proprietary technologies.